Examine emerging myostatin inhibition and its potential to preserve muscle during large modern weight-loss treatments and regimens.
Key Takeaways
- Meta-analysis of 22 trials found roughly 25% of weight loss was lean tissue
- New triple-agonist incretin therapy produced about 28% average body weight loss in trials
- Genetic loss of myostatin leads to dramatically increased muscle mass in animals and rare humans